Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Federal state budget military educational institution of higher professional education “Military medical Academy named after S. M. Kirov” Ministry of defense of the Russian Federation (St. Petersburg, Russian Federation)

    Keywords:Clostridium difficile infection,epidemiology,treatment,prevention

    Abstract:The review presents recent data on the prevalence and types of Clostridium difficile infection, about the circulation of the microorganism in the environment and the human population, the peculiarities of interaction with the normal microflora of the gastrointestinal tract that will allow for a fresh look at the epidemiology of diseases caused by this microorganism, to enhance the effectiveness of preventive interventions, to improve treatment outcomes.

      1. Magill S.S., Edwards J. R., Bamberg W., Beldavs Z. G., Dumyati G., Kainer MA. et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-208.
      2. Rupnik M., Wilcox M. H., Gerding D. N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev 2009; 7: 526-36.
      3. Gerding D.N., Lessa F. C. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am 2015; 29: 37-50.
      4. O’Brien J.A., Lahue B. J., Caro J. J., Davidson D. M. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-1227.
      5. Kuijper E.J., Coignard B., Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12(Suppl. 6): 2-18.
      6. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012; 18(Suppl. 6): 5-12.
      7. Desai, K., Gupta, S.B., Dubberke, E.R., Prabhu, V.S., Browne, C., Mast, T.C. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect. Dis. 2016; 16: 303.
      8. See I., Mu Y., Cohen J. et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58: 1394-1400.
      9. Elliott B., Androga G. O., Knight D. R., Riley T. V. Clostridium difficile infection: Evolution, phylogeny and molecular epidemiology. Infect Genet Evol. 2016 Dec 22; 49: 1-11.
      10. McDonald L.C., Coignard B., Dubberke E., Song X., Horan T., Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-145.
      11. van Beurden Y. H., Bomers M. K., van der Werff S. D., Pompe E. A.P.M., Spiering S., Vandenbroucke-Grauls C.M.J.E., Mulde C. J.J. Cost analysis of an outbreak of Clostridium difficile infection ribotype 027 in a Dutch tertiary care centre. Journal of Hospital Infection xxx (2017) 1-5.
      12. Cohen S.H., Gerding D. N., Johnson S., Kelly C. P., Loo V. G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
      13. Butler M., Bliss D., Drekonja D., Filice G., Rector T., MacDonald R., et al. Effectiveness of early diagnosis, prevention, and treatment of Clostridium difficile infection. Rockville (MD): Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2011.
      14. Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61: 157-62.
      15. Domeniconi G., Serafino S., De Amicis M. M., Formica S., Lanzoni M., Maraschini A., Sisto F., Consonni D., Cappellini M. D., Fabio G., Castaldi S. Clostridium difficile infection epidemiology and management: Comparison of results of a prospective study with a retrospective one in a reference teaching and research hospital in Northern Italy. Am. J. Infect. Control. 2016; 44: 1214-8.
      16. Khanna S., Pardi D. S., Aronson S. L., Kammer P. P., Orenstein R., Sauver J. L. St., Harmsen W. S., Zinsmeister A. R. The Epidemiology of Community-acquired Clostridium difficile infection: A population-based study. Am J Gastroenterol. 2012 Jan; 107(1): 89-95.
      17. McDonald L.C., Owings M., Jernigan, D. B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 2006; 12: 409-415.
      18. Worth L.J., Spelman T., Bull A. L., Brett J. A., Richards M. J. Epidemiology of Clostridium difficile infections in Australia: enhanced surveillance to evaluate time trends and severity of illness in Victoria, 2010-2014. J Hosp Infect. 2016 Jul;93(3):280-5.
      19. Furuya-Kanamori L., McKenzie S.J., Yakob L., Clark J., Paterson D. L., Riley T. V., Clements A. C. Clostridium difficile infection seasonality: patterns across hemispheres and continents - a systematic review. PLoS One 2015; 10: e0120730.
      20. Songer J.G., Uzal F. A. Clostridial enteric infections in pigs. J. Vet. Diagn. Investig. 2005; 17; 528-536.
      21. Båverud V., Gustafsson A., Franklin A., Aspan A., Gunnarsson A. Clostridium difficile: prevalence in horses and environment, and antimicrobial susceptibility. Equine Vet. J. 2003; 35; 465-471.
      22. Weese J. S. Clostridium difficile in food - innocent bystander or serious threat? Clin. Microbiol. Infect. 2010; 16; 3-10.
      23. Rodriguez C., Avesani V., Van Broeck J., Taminiau B., Delmée M., Daube G. Presence of Clostridium difficile in pigs and cattle intestinal contents and carcass contamination at the slaughterhouse in Belgium. Int J Food Microbiol. 2013 Sep 2; 166(2): 256-62.
      24. Rodriguez C., Taminiau B., Avesani V., Van Broeck J., Delmée M., Daube G. Multilocus sequence typing analysis and antibiotic resistance of Clostridium difficile strains isolated from retail meat and humans in Belgium. Food Microbiology. 2014; 42; 166-171.
      25. Rodriguez-Palacios A., Reid-Smith R.J., Staempfli H. R., Daignault D., Janecko N., Avery B. P., Martin H., Thomspon A. D., McDonald L.C., Limbago B., Weese J. S. Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg Infect Dis. 2009 May; 15(5): 802-5.
      26. Weese J.S., Avery B. P., Rousseau J., Reid-Smith R. J. Detection and enumeration of Clostridium difficile spores in retail beef and pork. Appl Environ Microbiol. 2009 Aug; 75(15): 5009-11.
      27. Bauer M.P., Notermans D. W., van Benthem, B.H., Brazier, J.S., Wilcox, M.H., Rupnik, M., Monnet, D.L., van Dissel, J.T., Kuijper, E. J. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377; 63-73.
      28. Rodriguez-Palacios A., Ilic S., LeJeune J. T. Clostridium difficile with Moxifloxacin/Clindamycin Resistance in Vegetables in Ohio, USA, and Prevalence Meta-Analysis. Journal of Pathogens. 2014, Article ID 158601, 7 p.
      29. Sjörberg M., Eriksson M., Andersson J., Noren T. Transmission of Clostridium difficile spores in isolation room environments and through hospital beds. APMIS. 2014 Sep;122(9):800-3.
      30. Alqumber M. A. Clostridium difficile in retail baskets, trolleys, conveyor belts, and plastic bags in Saudi Arabia, Saudi Med. J. 2014; 35: 1274-1277.
      31. del Mar Gamboa M., Rodriguez E., Vargas P. Diversity of mesophilic clostridia in Costa Rica soils, Anaerobe. 2005; 11: 322-326.
      32. Zidaric V., Beigot S., Lapajne S., Rupnik M. The occurrence and high diversity of Clostridium difficile genotypes in rivers, Anaerobe. 2010; 16: 371-375.
      33. Rodriguez C., Van Broeck J., Taminiau B., Delmée M., Daube G. Clostridium difficile infection: Early history, diagnosis and molecular strain typing methods. Microb Pathog. 2016 Aug; 97: 59-78. doi: 10.1016/j.micpath.2016.05.018.
      34. Yutin N., Galperin M. Y. A genomic update on clostridial phylogeny: Gramnegative spore formers and other misplaced clostridia. Environ. Microbiol. 2013; 15; 2631-2641.

    Full text is published :
    Zakharenko S.M. EPIDEMIOLOGICAL ASPECTS OF C. DIFFICILE INFECTION. Experimental and Clinical Gastroenterology Journal. 2017;139(03):67-70
    Read & Download full text

    1. Central state medical Academy (Moscow, Russian Federation)

    Keywords:bacterial overgrowth syndrome,inflammatory bowel disease

    Abstract:Review article devoted to the problem of small intestinal bacterial overgrowth syndrome (SIBO). This definition of the syndrome, epidemiology, clinical manifestations, diagnosis. Discussed the pathogenesis and the relationship SIBO with diseases of the gastrointestinal tract. The new studies SIBO in patients with inflammatory bowel disease.

      1. Ардатская М. Д. Синдром избыточного бактериального роста и нарушение процессов пищеварения и всасывания: патогенетическая нутриционная терапия//. Экспериментальная и клиническая гастроэнтерология. 2009; 6; С. 86-96.
      2. Ардатская М. Д., Минушкин О. Н. Синдром избыточного бактериального роста: определение, современные подходы к диагностике и лечебной коррекции.// Гастроэнтерология. 2012; 2: С. 45-49
      3. Ардатская М. Д. Синдром избыточного бактериального роста в тонкой кишке, современные методы диагностики и подходы к лечебной коррекции. //Медицинский совет 2016, 14: 88-95.
      4. Белоусова Е. А. Синдром избыточного бактериального роста тонкой кишки в свете общей концепции о дисбактериозе кишечника. Взгляд на проблему. //Фарматека, 2009, № 2.
      5. Логинов В.А. кандид. Дисс. Синдром избыточного бактериального роста у больных со сниженной кислотопродуцирующей функции желудка (клиническое значение, диагностика и лечение). М. 2015.
      6. Almeida J. A., Kim R., Stoita A., McIver C.J., Kurtovic J., Riordan S. M. Lactose malabsorption in the elderly: role of small intestinal bacterial overgrowth. Scand. J. Gastroenterol. 2008;43(2): 146-54.
      7. Bures J, Cyrany J, Kohoutova D, Fo¨ rstl M, Rejchrt S, Kvetina J, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol WJG 2010;16:2978-90.
      8. Carrara M., Desideri S., Azzurro M., Bulighin G. M. et al. Small intestine bacterial overgrowth in patients with irritablebowel syndrome. Eur. Rev. Med. Pharmacol. Sci. 2008 May-Jun;12(3):197-202.
      9. Castiglione F, Del Vecchio Blanco G, Rispo A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31:63-66.
      10. Chandra S, Dutta U, Noor MT, Taneja N, Kochhar R, Sharma M, et al. Endoscopic jejunal biopsy culture: a simple and effective method to study jejunal microflora. Indian J Gastroenterol 2010;29:226-30.
      11. Chang MS, Green PHR. A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease. Ther Adv Gastroenterol 2012;5:31-6.
      12. Chang MS, Minaya MT, Cheng J, Connor BA, Lewis SK, Green PHR. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci 2011;56:2939-46.
      13. Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR, Harmsen WS, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011;33:1059-67.
      14. Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci 2010;55: 124-30.
      15. Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2011;52:382-6.
      16. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011;41:380-6.)
      17. Daveson AJM, Anderson RP. Small bowel endoscopy and coeliac disease. Best Pract Res Clin Gastroenterol 2012;26:315-23.
      18. Dominguez-Munoz J. E. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr. Gastroenterol Rep. 2007
      19. Fairris GM, Ashworth J, Cotterill JA. A dermatosis associated with bacterial overgrowth in jejunal diverticula. Br J Dermatol 1985;112:709-13.
      20. Fundaro` C, Fantacci C, Ansuini V, Giorgio V, Filoni S, Barbaro F, et al. Fecal calprotectin concentration in children affected by SIBO. Eur Rev Med Pharmacol Sci 2011;15:1328-35.
      21. George N.S,. Sankineni A., Parkman H.P. Small Intestinal Bacterial Overgrowth in Gastroparesis Dig Dis Sci. 2012. Oct 5.
      22. Ghoshal UC. How to interpret hydrogen breath tests. J Neurogastroenterol Motil 2011;17:312-7.
      23. Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil 2010;16:40-6.
      24. Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010;53:849-55.
      25. Hutyra T, Iwan´ czak B. Bakteryjny przerost flory jelita cienkiego u dzieci Small bowel bacterial overgrowth in children Pediatr Wspo´ łczesna Gastroenterol Hepatol Z˙yw Dziecka 2010;12:130-4.
      26. Jouet P, Coffin B, Sabate J-M. Small intestinal bacterial overgrowth in patients with morbid obesity. Dig Dis Sci 2011;56:615. author reply 615-616.
      27. Jun DW, Kim KT, Lee OY, Chae JD, Son BK, Kim SH, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci 2010;55:1465-71.
      28. Kim K-M, Kim B-T, Lee D-J, Park S-B, Joo N-S, Kim Y-S, et al. Erosive esophagitis may be related to small intestinal bacterial overgrowth. Scand J Gastroenterol 2012;47:493-8.
      29. Lappinga PJ, Abraham SC, Murray JA, Vetter EA, Patel R, Wu T-T. Small intestinal bacterial overgrowth: histopathologic features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med 2010; 134: 264-70.
      30. Lakshmi CP, Ghoshal UC, Kumar S, Goel A, Misra A, Mohindra S, et al. Frequency and factors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liver and extra hepatic portal venous obstruction. Dig Dis Sci 2010;55:1142-8.
      31. Leiby A, Mehta D, Gopalareddy V, Jackson-Walker S, Horvath K. Bacterial overgrowth and methane production in children with encopresis. J Pediatr 2010;156:766-70. 770.e1.
      32. Leung Ki EL, Roduit J, Delarive J, Guyot J, Michetti P, Dorta G. Small intestine bacterial overgrowth. Rev Me´ dicale Suisse 2010;6:186-8. 190-1.
      33. Łokiec´ K, Klupin´ska G, Walecka-Kapica E, Błon´ ska A. Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome. Pol Merkur Lek Organ Pol Tow Lek 2014;36: 307-10.
      34. Lin H. C. Small intestinal bacterial overgrowth: aframework for understanding irritable bowel syndrome.JAMA. 2004. Aug 18; 292(7): 852-8.
      35. Lisowska A, Pogorzelski A, Oracz G, Skorupa W, Cofta S, Socha J, et al. Small intestine bacterial overgrowth and fat digestion and absorption in cystic fibrosis patients. Acta Sci Pol Technol Aliment 2010;9:477-83.
      36. Lisowska A, Wo´ jtowicz J, Walkowiak J. Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection. Acta Biochim Pol 2009;56:631-4.
      37. Lisowska A, Pogorzelski A, Oracz G, Siuda K, Skorupa W, Rachel M, et al. Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth. J Cyst Fibros 2011;10:418-21.
      38. Lombardo L., Foti M., Ruggia O., Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy Clin. Gastroenterol. Hepatol. 2010.Jun;8(6): 504-8.
      39. Madrid AM, Poniachik J, Quera R, Defilippi C. Small intestinal clustered contractions and bacterial overgrowth: a frequent finding in obese patients. Dig Dis Sci 2011;56:155-60.
      40. Miazga A. et al. / Advances in Medical Sciences 60 (2015) 118-124
      41. Mitchell DM, Henao MP, Finkelstein JS, Burnett-Bowie S-AM. Prevalence and predictors of vitamin D deficiency in healthy adults. Endocr Pract 2012;18: 914-23.
      42. Ojetti V, Pitocco D, Scarpellini E, Zaccardi F, Scaldaferri F, Gigante G, et al. Small bowel bacterial overgrowth and type 1 diabetes. Eur Rev Med Pharmacol Sci 2009;13:419-23.
      43. Pande C., Kumar A., Sarin S. K. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver diseaseAliment Pharmacol Ther. 2009. Jun 15; 29(12): 1273-81.
      44. Park JS, Yu JH, Lim HC, Kim JH, Yoon YH, Park HJ, et al. Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome. Korean J Gastroenterol Taehan Sohwagi Hakhoe Chi 2010;56:242-8.
      45. Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008;103:1257-62.
      46. Pimentel M. Evaluating a bacterial hypothesis in IBS using a modification of Koch’s postulates: part 1. Am J Gastroenterol 2010;105:718-21.
      47. Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48:86-92.
      48. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci 2012;57:1321-9.
      49. Rana SV, Sharma S, Kaur J, Sinha SK, Singh K. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion 2012;85:243-7.
      50. Rana S, Bhansali A, Bhadada S, Sharma S, Kaur J, Singh K. Orocecal transit time and small intestinal bacterial overgrowth in type 2 diabetes patients from North India. Diabetes Technol Ther 2011;13:1115-20.
      51. Rana SV, et al. Small Intestinal Bacterial Overgrowth and Orocecal Transit Time in Patients of Inflammatory Bowel DiseaseDig Dis Sci (2013) 58:2594-2598).
      52. Rana SV, et al. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients, J Crohns Colitis (2014).
      53. Ratuapli SK, Ellington TG, O’Neill M-T, Umar SB, Harris LA, Foxx-Orenstein AE, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012;107:730-5.
      54. Romond M-B, Colavizza M, Romond PC, Bezirtzoglou E. Selective decontamination by antimicrobials during long term treatment: perspectives for saving host indigenous microbiota. Anaerobe 2011;17:468-73.
      55. Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol 2011;26(Suppl. 3):135-8.
      56. Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis 2013;4:223-31.
      57. Schommer K, Reljic D, Ba¨rtsch P, Sauer P. Gastrointestinal complaints in runners are not due to small intestinal bacterial overgrowth. J Negat Results Biomed 2011;10:8.
      58. Singh, V. V., Toskes, P. P. Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment // Curr Treat Options Gastroenterol. 2004; 7 (1): 19-28.
      59. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci 2010;55:2441-9.
      60. Spiegel BMR. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastro-enterol Hepatol 2011;9:461-9. quiz e59.
      61. Tarnopolsky MA, Pearce E, Matteliano A, James C, Armstrong D. Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable. Muscle Nerve 2010;42:853-5.
      62. Shanab AA, Scully P, Crosbie O, Buckley M, O’Mahony L, Shanahan F, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56:1524-34.
      63. Weinstock LB, Walters AS. Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth. Sleep Med 2011;12:610-3.
      64. Wilder-Smith CH, Materna A, Wermelinger C, Schuler J. Fructose and lactose intolerance and malabsorption testing: the relationship with symptoms in functional gastrointestinal disorders. Aliment Pharmacol Ther2013;37:1074-83.
      65. Yakoob J, Abbas Z, Khan R, Hamid S, Awan S, Jafri W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol 2011;17:371-5.
      66. Zhao J, Fox M, Cong Y, Chu H, Shang Y, Fried M, et al. Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010;31:892-900.
      67. Zoetendal EG, Raes J, van den Bogert B, Arumugam M, Booijink CCGM, Troost FJ, et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J 2012;6:1415-26.

    Full text is published :
    Topchy T.V., Minushkin O.N., Skibina Y.S,, Evsikov A.E. THE BACTERIAL OVERGROWTH SYNDROME IN CLINICAL PRACTICE. Experimental and Clinical Gastroenterology Journal. 2017;139(03):71-78
    Read & Download full text

    1. Russian Medical Academy of Continuous Professional Education (Moscow, Russian Federation)

    Keywords:gut microbiota,obesity,metabolics diseases

    Abstract:The review deals modern ideas about mechanisms of obesity development due to disorders of gut microbiota, prospects of using probiotics and prebiotics in treatment of metabolics diseases.

      1. Андрианова О. Л., Мирсаева Г. Х., Ибрагимова Л. А. Эффективная стратегия ожирения// Эндокринология.-2015.-№ 3.-С.51-56.
      2. Гарднер Д., Шобек Д. Базисная и клиническая эндокринология. - 2011.-Кн.1, М.: Бином.
      3. Григорьев А. В. Желудочно-кишечный тракт как среда обитания микробов. Раздел 1. Морфология желудочно-кишечного бактериального биотопа. - 2004.-М.: СИЛМА. - 123 с.
      4. Лоранская И. Д., Болдырева М. Н., Лаврентьева О. А., Мулухова Э. В. Пристеночная микрофлора кишечника. М.: Прима Принт.-2015.-100 с.
      5. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. Методические рекомендации МР М.: Федеральная служба по надзору в сфере защиты прав потребителя и благополучия человека.-2008.
      6. Шварц В. Жировая ткань как эндокринный орган.// Проблемы эндокринологии. - 2009. - Т. 55, № 1. С. 38-44.
      7. Aguirre M., Venema K. The use of fecal samples for studying human obesity.//Europ. J. of Epidemiology.-2015. - 30.-P.1067-1069.
      8. Al Mushref M. and Srinivasan S. Effect of high fat-diet and obesity on gastrointestinal motility.//Annals of Translational Medicine.2013,1, 14.
      9. Backhed F., Manchester J. K., Semenkovich C. F., Gordon J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. // Proc. Natl. Acad. Sci. USA. - 2007. - V. 104. - P. 979-984.
      10. Blaser M. J. Missing Microbes. New York: Henry Holt and Company, LLC. 2014. 274 pp.
      11. Caesar R., Fak F., Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism.//J Intern Med 2010. - 268 (4).-P.320-328.
      12. Canfora E. E., Jocken J. W., Black E. E. Short-chain fatty acids in control of body weight and insulin sensitivity.//Nat Rev Endocrinol.-2015,11. - P. 297-313.
      13. Chambers E. S. et. al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.//Gut,2015, 64. - P. 1744-1754.
      14. Collado M. C., Isolauri E., Laitinen K. and Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women.//Am J Clin Nutrition.-2008,88. - P. 894-899.
      15. Cox L. M., Blaser M. J. Pathways in microbe-induced obesity.//Cell Metabolism.-2013. - 17(6). - P. 883-894.
      16. David L. A., Maurice C. F., Carmody R. N. et. al. Diet rapidly and reproducibly alters the human gut microbiome.//Nature.-2014.-505. - P. 559-563.
      17. De Filippo C., Cavalieri D., Di Paola M. et. al. Impact of diet shaping gut microbiota revealed by а comparative study in children from Europe and rural Africa.//Proc Natl Acad Sci.-2010.-107.-P.14691-14696.
      18. de Wit N., Derrien M., Bosch-Vermeulen H. et. al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine.// Am J.of Phys Gastrointestinal Liver Phy.2012. - 303(5). - G589-G599.
      19. Degen D. L. and Phillips S. F. Variability of gastrointestinal transit in healthy women and men.//Gut.1996.-39. - P. 299-305.
      20. DeWeerdt S. Microbiome: A complicated relation-ship status.//Nature.-2014.-508. - S 61-63.
      21. Dowsey M. M., Choong P. F. M. Obese diabetic patients are at substantial risk for deep infection after primary TKA. // Clin Orthop Relat Res. - 2009. - V. 467(6). - P. 1577-1581.
      22. Fried M., Hainer V., Basdevant A. et. al. Interdisciplinary European guidelines on surgery of severe obesity.//Obes. Facts.-2008. - Vol. 1. - P. 52-59.
      23. Furet J. P., Kong L. C., Tap J. et. al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers.//Diabetes. - 2010. - 59. - P. 3049-3057.
      24. Gaci N., Borrel G., Tottey W. et. al. Archea and the human gut: new beginning of an old story.//World J. of Gastroenterology.2014.-20.-P.16062-16078.
      25. Gasbarrini A. The gut microbiota. The 4 organ of the digestive system.Composition, functions and related diseases. Verduci Editore.-2013. - 74 p.
      26. Karlsson С. L., Onnerfalt J., Xu J. et. al. The microbiota of the gut in pre-school children with normal and excessive body weight.//Obesity.2012, 20. - P. 2257-2261.
      27. Keenan M. J. et. al. Role of resistant starch in improving gut health, adiposity and insulin resistance.//Adv Nutr 2015. - 6.-P.198-205.
      28. Khan M. Y. et al. A review on obesity and its management.// Int. Journal of Scientific & Engineering Research- 2012. - Volume 3, Issue 11.
      29. Krznarić Z, Vranešić Bender D, Kunović A, Kekez D, Stimac D. Gut Microbiota and Obesity.// Dig Dis. - 2012. - 30(2). - Р.196-200.
      30. Le Chatelier E., Nielsen T., Qin J. et. al. Richness of human gut microbiome correlates with metabolic markers.//Nature. - 2014. - 500. - P. 541-546.
      31. Ley R. E., Backhed F., Turnbaugh P., Lozupone C. A., Knight R. D. and Gordon J. I. Obesity alters gut microbial ecology.// Proc. Natl. Acad. Sci.USA.-2005.-V. 102. - P. 11070-11075.
      32. Ley R. E., Turnbaugh P. J., Klein S. and Gordon J. I. Microbial ecology: human gut microbes associated with obesity.//Nature.-2006.-444. - P. 1022-1023.
      33. Lin H. V. et. al. Butirate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor3 - independent mechanisms. //PLoS One 7.-2012, e35240.
      34. Lu Y., Fan C., Li P. et. al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota.//Nature, 2016.-6. - P. 1-13.
      35. Marteau P. The gut microbiota in 20 questions. John Libbey Eurotext.-2014. - 42p.
      36. Nam Y.-D., Jung M.-J., Roh S. W. et. al. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. 2011. - PloS One 6. - e22109.
      37. Roberts K. T., Allen-Vercoe E., Williams S. A. et. al. Comparative study of the in vitro fermentative characteristics of fenugreek gum, white bread and bread with fenugreek gum using human faecal microbes.// Bioactive Carbohydrates and Dietary Fibre. 2015,5. - P. 116-124.
      38. Scarpellini E., Tack J. Obesity and metabolic syndrome: an inflammatory condition.//Dig Dis 2012. - 30 (2). - P. 148-153.
      39. Tan J. et. al. The role of short-chain fatty acids in health and disease.//Adv Immunol.-2014.-121, P. 91-119.
      40. Torralladona D., Harris C. I. and Fuller M. F. Pigs gastrointestinal microflora provide them with essential amino acids.//J. of Nutrition. 2003.-133.-P.1127-1131.
      41. Tremalori V., Backhed F. Functional interactions between the gut microbiota and host metabolism.//Nature.-2012. - 489(7415). - P. 242-249.
      42. Walker A. W. et. al. pH and peptide supply can radically alter bacterial population and short-chain fatty acids ratios within microbial communities from the human colon.//Appl Environ Microbiol.-2005,71. - P. 3692-3700.
      43. Zhang M., Yang X.-J. Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases.// World J. of Gastroenterology. 2016. - 22(40). - P. 8905-8909.

    Full text is published :
    Loranskaya I.D., Stepanova E.V., Kupaeva V.A. GUT MICROBIOTA AND OBESITY. Experimental and Clinical Gastroenterology Journal. 2017;139(03):79-83
    Read & Download full text

    1. “Moscow state medical dental University named A. I. Evdokimov” Ministry of health of the Russian Federation (Moscow, Russian Federation)
    2. “Central clinical hospital № 2 of them. N.. Semashko” JSC “Russian Railways” (Moscow, Russian Federation)

    Keywords:functional diarrhea,Rome criteria IV,diagnosis

    Abstract:The achievements of basic and clinical science over the past 10 years in the study of epidemiology, etiology, pathophysiology, diagnosis and therapy of functional disorders of the intestine necessitated the revision existed since 2006, the Rome III criteria. In may 2016 the global gastroenterology community on the American gastroenterological week met with Roman criteria IV, the main provisions of the consensus are presented in this publication. Functional bowel disease continues to include clinical disease as irritable bowel syndrome, functional constipation, functional diarrhea, functional abdominal bloating, and nonspecific functional bowel disorders. Unlike the previous classification in the section of functional bowel diseases has a new form - opioid-induced constipation, designed to draw attention of clinicians on the sharply increased frequency of use of opiates and associated with a large number of side effects in their application. Roman urges the Committee not to consider this form as a separate disease, and to classify the developed clinical picture as opioid-induced adverse effects. Functional diarrhea (FD) is characterized by the persistence loose or watery stools, an important distinguishing criterion for diagnosis is not a criteria of IBS, i. e. in this disorder of stool abdominal pain or bloating certainly can be present but are never dominant symptoms. In addition to these changes, according to the study, Whitehead W. E. et al. for the diagnosis of functional diarrhea is the criterion of the frequency of episodes of liquid stools or watery stools was reduced from 75 % to 25 %

      1. Маев И. В., Черемушкин С. В. Синдром раздраженного кишечника. Римские критерии III. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2007. № 1. С. 29-33.
      2. Brian E. Lacy, Fermín Mearin, Lin Chang, William D. Chey, Anthony J. Lembo, Magnus Simren, and Robin Spiller. Bowel Disorders. Gastroenterology 2016;150:1393-1407.
      3. Маев И. В., Черемушкин С. В., Кучерявый Ю. А., Черемушкина Н. В. Синдром раздраженного кишечника. Римские критерии IV. Consilium medicum, № 8, vol. 18, С. 79-85, 2016.
      4. Whitehead WE, Palsson OS. Report on Rome Normative GI Symptom Survey. 2014.
      5. Porter CK, Gormley R, Tribble DR, et al. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011;106:130-138.
      6. Zhao YF, Guo XJ, Zhang ZS, et al. Epidemiology of functional diarrhea and comparison with diarrhea predominant irritable bowel syndrome: a populationbased survey in China. PLoS One 2012;7: e43749.
      7. Sorouri M, Pourhoseingholi MA, Vahedi M, et al. Functional bowel disorders in Iranian population using Rome III criteria. Saud J Gastroenterol 2010;16:154-160.
      8. Chang F-Y, Chen P-H, Wu T-C, et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr 2012;21:594-600.
      9. Schiller LR, Pardi DS, Sellin JH. Clin Gastroenterol Hepatol. 2017 Feb;15(2):182-193.e3. doi: 10.1016/j.cgh.2016.07.028. Review.
      10. Tack J. Functional diarrhea. Gastroenterol Clin North Am 2012;41:629-637.
      11. Choi MG, Camilleri M, O’Brien MD, et al. A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia. Am J Gastroenterol 1997;92:297-302.
      12. Zanini B, Ricci C, Bandera F, et al. Incidence of postinfectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012;107:891-899.).
      13. Parry SD, Stansfield R, Jelley D, et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, casecontrol study. Am J Gastroenterol 2003;98:1970-1975.
      14. Hobbis IC, Turpin G, Read NW. Abnormal illness behaviour and locus of control in patients with functional bowel disorders. Br J Health Psychol 2003;8:393-408.
      15. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32:920-924.
      16. Маев И. В., Черемушкин С. В., Кучерявый Ю. А. Синдром раздраженного кишечника. Римские критерии IV. О роли висцеральной гиперчувствительности и способах ее коррекции. Методическое пособие. М., 2016.
      17. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480-1491.
      18. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912-2917.
      19. Маев И. В., Кучерявый Ю. А., Андреев Д. Н., Черёмушкин С. В. Эволюция представлений о микроскопическом колите. Терапевтический архив. 2015. Т. 87. № 4. С. 69-76.
      20. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-468.
      21. Fernández-Bañares F, Rosinach M, Piqueras M, et al. Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea. Aliment Pharmacol Ther 2015;41:1132-1140.

    Full text is published :
    Cheremushkin S.V., Kucheryavy Y.A., Cheremushkina N.V., Maev I.V. FUNCTIONAL DIARRHEA. ROME CRITERIA IV. Experimental and Clinical Gastroenterology Journal. 2017;139(03):84-88
    Read & Download full text